iShares US Pharmaceuticals ETF
91 hedge funds and large institutions have $83.7M invested in iShares US Pharmaceuticals ETF in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 24 reducing their positions, and 11 closing their positions.
196% more call options, than puts
Call options by funds: $1.55M | Put options by funds: $525K
38% more capital invested
Capital invested by funds: $60.8M → $83.7M (+$22.9M)
21% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 24
6.43% more ownership
Funds ownership: 66.05% → 72.49% (+6.4%)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
1% less funds holding
Funds holding: 92 → 91 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5.18M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.2M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.38M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.28M |
| 5 |
SPIA
Steward Partners Investment Advisory
New York
|
+$1.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
-$976K |
| 2 |
Jane Street
New York
|
-$868K |
| 3 |
SRSA
S.R. Schill & Associates
Mercer Island,
Washington
|
-$484K |
| 4 |
ST
Spinnaker Trust
Portland,
Maine
|
-$450K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$350K |
IHE Hedge Fund Activity: Q2 2020 in Review
91 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2020, worth a combined $83.7M — up 38% from $60.8M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new IHE positions and 11 closed out — a net gain of 1 holder — while 29 added to existing stakes and 24 trimmed.
The largest buyer was Royal Bank of Canada, adding an estimated $5.18M. The largest seller was Fisher Asset Management, cutting an estimated $976K.
- 91 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2020, down from 92 in Q1 2020.
- Funds reported $83.7M of iShares US Pharmaceuticals ETF stock for Q2 2020, up 38% quarter-over-quarter.
- 12 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2020 and 11 closed out, a net change of +1 holder.
- The largest iShares US Pharmaceuticals ETF buyer in Q2 2020 was Royal Bank of Canada, an estimated $5.18M added.
- The largest iShares US Pharmaceuticals ETF seller in Q2 2020 was Fisher Asset Management, an estimated $976K sold.
Based on aggregated 13F filings for Q2 2020.